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ABSTRACT
The transcription factor Sox5 has previously been
shown in chicken to be expressed in early neural
crest cells and neural crest-derived peripheral glia.
Here, we show in mouse that Sox5 expression also
continues after neural crest specification in the
melanocyte lineage. Despite its continued expres-
sion, Sox5 has little impact on melanocyte develop-
ment on its own as generation of melanoblasts
and melanocytes is unaltered in Sox5-deficient
mice. Loss of Sox5, however, partially rescued
the strongly reduced melanoblast generation and
marker gene expression in Sox10 heterozygous
mice arguing that Sox5 functions in the melanocyte
lineage by modulating Sox10 activity. This modula-
tory activity involved Sox5 binding and recruitment
of CtBP2 and HDAC1 to the regulatory regions of
melanocytic Sox10 target genes and direct inhibi-
tion of Sox10-dependent promoter activation. Both
binding site competition and recruitment of core-
pressors thus help Sox5 to modulate the activity of
Sox10 in the melanocyte lineage.
INTRODUCTION
Many transcription factors of the Sox protein family are
widely expressed in the vertebrate embryo and represent
important developmental regulators (1,2). Several sub-
groups can be distinguished, one of them is the SoxD
group. SoxD proteins do not only share a high degree of
amino acid similarity, but also a number of biochemical
features that make them unique among Sox proteins. For
one, SoxD proteins exist in several isoforms that are gen-
erated by alternative splicing from rather large genes with
multiple exons (3). This is uncommon for Sox proteins
which are usually encoded by intronless genes or compact
genes with few exons (2). As a consequence, SoxD proteins
exist in short and long isoforms. Only the long isoforms
contain a characteristic coiled-coil domain that allows
these proteins to homodimerize or heterodimerize with
other SoxD proteins (3). In fact, the long SoxD isoforms
are the only Sox proteins known to exist as dimers in
solution. SoxD proteins furthermore diﬀer from other
Sox proteins in that they do not appear to have a typical
transactivation domain (3) arguing that SoxD proteins
inﬂuence transcription in other ways.
Vertebrates possess the three highly related proteins
Sox5, Sox6 and Sox13 (3–5). Each of them is expressed
widely during embryogenesis. All three SoxD genes have
been deleted in the mouse and found to inﬂuence a wide
range of developmental processes including the develop-
ment of chondrocytes, oligodendrocytes, corticofugal neu-
rons, erythrocytes, T lymphocytes, the notochord and the
heart (6–13). During some of these events, SoxD proteins
primarily function as modulators of the SoxE proteins
Sox9 and Sox10 (3,7,9), whereas this is not the case in
other developmental processes (10,13). Sox5, in particular,
has been found to inﬂuence chondrocyte development by
cooperating with and reinforcing the activity of Sox9 on
several of its chondrocytic target genes (3,14), whereas its
impact on oligodendrocyte maturation appears to be pri-
marily due to its ability to counteract the activity of Sox10
on several of its oligodendroglial target genes (9). In agree-
ment with its numerous functions, Sox5 cannot be deleted
in mice without severe consequences and Sox5-deﬁcient
mice die at birth because of respiratory distress (7).
In the chicken, Sox5 is also expressed in the neural crest
(15). In the cranial neural crest, Sox5 was found in pre-
migratory and migratory neural crest cells, but also in
some neural crest derivatives, in particular in the glial
components of the peripheral nerves and ganglia (15,16).
Its importance for neural crest development had further-
more been inferred from ectopic expression in the electro-
porated neural tube, where it promoted the generation of
additional neural crest cells. Sox5 also occurs in neural
crest cells of the mouse (C.S. and M.W., unpublished
data). Whether its role in the neural crest involves a func-
tional interplay with Sox9 or Sox10 has not been analyzed
so far. It has to be noted, however, that both Sox9 and
Sox10 are strongly expressed in the neural crest and reg-
ulate various phases of neural crest development. Sox9,
for instance, is involved in deﬁning the premigratory
neural crest cell, ensures its survival and allows its
epithelial-to-mesenchymal transition, whereas Sox10 is
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maintenance of their pluripotency (17,18). Additionally,
both SoxE proteins inﬂuence several cell fate decisions in
the neural crest at later stages of development, with Sox9
being important for acquisition of the chondrocytic fate of
cranial neural crest cells and Sox10 driving glial and mela-
nocytic speciﬁcation (19,20).
Melanocytes are derived from neural crest cells that
migrate on a dorsolateral pathway immediately below
the epidermis. Cells speciﬁed to become melanoblasts are
recognizable by their expression of several markers,
including the receptor tyrosine kinase c-Kit, the dopa-
chrome tautomerase Dct and the basic helix–loop–helix
transcription factor Mitf (21). In fact, Mitf is the master
regulator of melanocyte development and the onset of its
expression during development distinguishes a migrating
neural crest cell from a melanoblast (21). Induction of
Mitf expression in the speciﬁed melanoblast is dependent
on Sox10 and Pax3, thus explaining why Sox10 is essential
for melanocyte development (19,22–24). There is good
evidence that Mitf is a direct target gene of Sox10
and probably also of Pax3 in neural crest cells (25–29).
Once induced, Mitf has to be stimulated in its activity by
ERK-dependent phosphorylation upon c-Kit activation
(30). One of the earliest genes induced by Mitf in melano-
blasts is Dct and this induction occurs in synergy with
Sox10 (31–34). In contrast to the functions of Sox10,
Mitf and c-Kit in melanoblasts, those of Dct are not
known, but seem to be nonessential and diﬀerent from
its later role in melanin production in diﬀerentiated mela-
nocytes (35).
Here, we report that Sox5 is expressed in melanoblasts
during mouse development and analyze its function, in
particular, in relation to Sox10 as a known major regula-
tor of melanocyte development.
MATERIALS AND METHODS
Animalhusbandry, genotyping, tissuepreparation,
immunohistochemistry and insitu hybridization
Starting with Sox10
+/lacZ mice (19) on a pure C3HeB/FeJ
genetic background and Sox5
+/  mice (7) backcrossed for
at least four generation on the same C3HeB/FeJ back-
ground, double heterozygous mice were obtained whose
intercrossing or breeding with Sox5
+/  mice generated
oﬀspring with various combinations of Sox5
  and
Sox10
lacZ alleles. Genotyping was performed by PCR as
reported. Embryos were isolated at 10.5, 11.5, 12.5, 16.5
and 18.5 days postcoitum (dpc) from staged pregnancies,
pups were sacriﬁced at postnatal days 3 and 7. At 10.5
dpc, care was taken that all embryos for further analyses
had comparable size and somite numbers.
For immunohistochemistry, embryos underwent ﬁxa-
tion in 4% paraformaldehyde before cryoprotection by
overnight incubation at 48C in 30% sucrose, embedding
in OCT compound at  808C and sectioning on a Leica
cryotome (Bensheim, Germany) (36,37). Immunohisto-
chemistry was performed on 10mm thick sections with
anti-Sox10 guinea pig antiserum (1:1000 dilution; 38),
anti-Sox9 guinea pig antiserum (1:500 dilution, 36),
anti-Sox13 guinea pig antiserum (1:1,000 dilution; gener-
ated against amino acids 566–588 of mouse Sox13 accord-
ing to accession number Q04891), anti-Sox6 guinea pig
antiserum (1:1000 dilution; 9), anti-Sox5 guinea pig anti-
serum (1:500 dilution; 9), anti-Sox5 rabbit antiserum
(1:4000 dilution; 15), anti-L-Sox5 rabbit antiserum
(1:500 dilution, gift of V. Lefebvre, Lerner Institute,
Cleveland, Ohio), anti-Sox13 rabbit antiserum (1:2000
dilution; Chemicon, Hofheim, Germany) and anti-Mitf
rabbit antiserum (1:2000 dilution, gift of H. Arnheiter,
NIH, Bethesda). Secondary antibodies conjugated to
Cy2, Cy3 (Dianova, Hamburg, Germany) or Alexa (Mole-
cular Probes, Go ¨ ttingen, Germany) immunoﬂuorescent
dyes were used for detection. Immunoﬂuorescence was
detected and documented with a Leica inverted micro-
scope (DMIRB) equipped with a cooled SPOT CCD
camera (Diagnostic Instruments, Sterling Heights,
MI, USA).
For whole-mount in situ hybridizations, embryos were
ﬁxed overnight at 48C in 4% paraformaldehyde, dehy-
drated, bleached and rehydrated. In situ hybridization
was performed essentially as described with DIG-labeled
antisense riboprobes for c-Kit, Dct and Mitf (19,25). All
steps except probe hybridization and ﬁnal colorimetric
detection were performed automatically on a Biolane
HTI (Ho ¨ lle & Hu ¨ ttner AG, Tu ¨ bingen, Germany). In situ
hybridizations were analyzed and documented with a
Leica MZFLIII stereomicroscope equipped with an
Axiocam (Zeiss, Oberkochem, Germany).
Cell culture, RT–PCR and luciferase assays
Neuro2a neuroblastoma cells were maintained in DMEM
containing 5% FCS, and B16 melanoma cells were grown
in DMEM containing 10% FCS. Both cell lines were
transfected using Superfect reagent (Qiagen, Hilden,
Germany).
For luciferase assays, cells were transfected transiently
in duplicates in 24-well plates or 3.5-cm dishes with 500ng
of luciferase reporter plasmid and 100ng of eﬀector or
shRNA expression plasmids per well/dish if not stated
otherwise. Luciferase reporters containing the Mitf pro-
moter (positions  1486 to +97; 25) or the Dct promoter
(positions  685 to +443; 32) were used. Eﬀector plasmids
corresponded to pCMV5-based expression plasmids for
Sox10, the long and short isoforms of Sox5 (9,39,40),
myc-tagged HDAC1 (gift of S. Minucci, European
Institute of Oncology, Milan, Italy) and HA-tagged
CtBP2 (gift of G. Chinnadurai, St Louis University
School of Medicine, St Louis, USA). For shRNA expres-
sion plasmids, regions corresponding to positions 966–984
of mouse Sox10 (Genbank accession number BC023356),
to positions 1415–1433 of mouse Sox5 (Genbank acces-
sion number NM_011444.1) and to positions 1135–1153
of mouse Sox6 (Genbank accession number U32614)
were each inserted between the BglII and XhoI sites
of the pSUPER.neo+gfp vector (Oligoengine, Seattle,
USA). Scrambled versions were inserted into
pSUPER.neo+gfp as controls.
For luciferase assays, cells were harvested and acti-
vities determined 48h posttransfection (41). In select
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transfected to normalize luciferase activities to b-galacto-
sidase activities. This normalization did not alter the
obtained results.
Immunocytochemistry was performed on B16 mela-
noma cells at 30% conﬂuency before transfection or 24h
after transfection with shRNA expression plasmids using
the anti-L-Sox5, anti-Sox6, anti-Sox9, anti-Sox10, anti-
Sox13, anti-Mitf and secondary antibodies described
above at 5-fold higher dilution. Transfected cells were
identiﬁed by GFP autoﬂuorescence.
RNA was prepared from B16 melanoma cells and spinal
cords of 7-day old mice using Trizol reagent (Invitrogen,
Karlsruhe, Germany). After reverse transcription to
cDNA, semiquantitative PCR was performed to detect
products speciﬁc for Sox5 (50-AGCCCCACATAAAG
CGTCCAAT-30 and 50-GGTCCTCCTCCTCCTCATC
GTA-30), Sox6 (50-AGCAGAGCCTGTGAAGTCC-30
and 50-CTTTGCTTCCTTCTG CGTCC-30), Sox9 (50-G
AACAGACTCACATCTCTCC-30 and 50-TGCTGCTTC
GACATCCACAC-30), Sox10 (50-GTCAGATGGGAA
CCCAGAGCAC-30 and 50- CCCGTAGCCAGCTG
CCGAG-30), Sox13 (50-AGCAAGATCCTTGGTTC
TCG-30 and 50-GGAGACTGCAGGTATTGATG-30),
Dct (50-TTCCAGAACTCAGGAGTGG-30 and 50- CAT
TGCTCACGGTCATCC-30), Mitf (50-AAGAGAGGCA
GAAAAAGGAC-30 and 50-GTTGTTGGTAAAGGTG
ATGG-30)o r -actin (50-CCTGGGCATGGAGTCCTG-
30 and 50-GGAGCAATGATCTTGAT CTTC-30).
Extract preparation, electrophoretic mobility shift
assayand western blot
Extracts from untransfected B16 cells (10-cm dishes) or
Neuro2a cells transfected with expression plasmids for
the long and short Sox5 isoforms, Sox10 or the carboxy-
terminally shortened MIC version of Sox10 (amino acids
1–189) were prepared as described (42). With these
extracts, electrophoretic mobility shift assay (EMSA)
was performed in the presence of poly(dGdC) as unspeci-
ﬁc competitor using
32P-labeled oligonucleotides contain-
ing the dimeric binding site S4/40 (50-GGGAGGTCT
ATAAAGGGCCTTTGACGGAATGC-30, positions
 310 to  282) and the monomeric binding site S1 (50-G
GGGGTCATGTGCTAACAAAGAGGATTTC TCT-30,
positions  150 to  121) from the Dct promoter, or the
Sox10 binding site 5 from the Mitf promoter (50-GGGA
CCATTGTCCATTAATACTACTGGAACTA-30, posi-
tions  270 to  242) as probes. For supershift experi-
ments, anti-Sox10 or anti-Sox5 antisera were added.
Extracts were also subjected to SDS–PAGE. Western
blotting was performed using speciﬁc antisera against
Sox5 (1:3000 dilution), Sox10 (1:5000 dilution) and
acetylated a-tubulin (1:2000 dilution; Sigma,
Taufkirchen, Germany) as primary antibodies, and horse-
radish peroxidase-coupled secondary antibodies with
enhanced chemiluminescence.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays on B16 cells
and transfected Neuro2a cells were performed as
described (43). Brieﬂy, cellular protein and genomic
DNA were cross-linked by treatment with 1% formalde-
hyde before chromatin extraction and sonication
to an average fragment length of 300–600bp.
Immunoprecipitations were performed overnight at 48C
using polyclonal IgG against Sox10 and Sox5 from
guinea pig, as well as mouse monoclonals against
HDAC1 (clone 2E10, Millipore, Schwalbach, Germany),
CtBP2 (clone 16, BD Transduction Laboratories,
Heidelberg, Germany) or the HA epitope (clone 12CA5).
DNA was puriﬁed from precipitates after cross-link rever-
sal and subjected to PCR. For detection of the Mitf pro-
moter (positions  369 to  125), 50-TTGGCCATT
AGGGAAGTCTC-30 and 50-CAGTTTCCCTGCTGGC
TTGA-30 were used as primers in 33 cycles of standard
PCR using an annealing temperature of 608C. A control
region from the Mitf upstream region (positions  5993 to
 5641) was probed with 50-GTGGCTCTTAGCTGT
TCTCT-30 and 50-GCTCTGGAAGGCTACATATC-30
as primers. The 50-CAGGAGGATGCCTAATTGTG-30
and 50-GACTTCCCAGTGCGTCAATA-30 were
employed to detect the Dct promoter (positions  457 to
 271), primers 50-GGCAACACCACATCCTGTAT-30
and 50-ACGATTGGTCCTGGAGAAGT-30 to amplify
a distal fragment from the Dct upstream region (positions
 40080 to  39738).
RESULTS
Sox5isexpressed in themelanocyte lineage
ofthe mouse embryo
Sox5 had previously been detected in the early migrating
neural crest of chicken (15) and is similarly expressed in
the mouse neural crest (C.S. and M.W., unpublished
data). To study whether Sox5 expression continues in
those migrating neural crest cells that become speciﬁed
to melanoblasts, we performed colabeling studies on
mouse embryos at 11.5 dpc (Figure 1). Using antibodies
directed against Sox10, migrating neural crest-derived
cells were identiﬁed in the trunk region immediately
below the epidermis (Figure 1B, C, F and G). These
cells were also labeled by Sox5-speciﬁc antibodies includ-
ing those that recognized all Sox5 isoforms (Figure 1A
and C) and those that speciﬁcally recognized the long
Sox5 isoforms (Figure 1E and G). To conﬁrm that these
Sox5-positive neural crest-derived cells corresponded to
melanoblasts, we performed additional colabeling with
antibodies directed against Mitf (Figure 1J). Signiﬁcant
amounts of Sox5 were present in Mitf-positive cells
(Figure 1I) indicating that Sox5 is indeed expressed in
the melanocyte lineage (Figure 1K and L). The melano-
cyte lineage thus represents one of several cell types in
which Sox5 and Sox10 are coexpressed (9,16).
Whereas most Mitf-positive cells contained Sox5at
10.5, 11.5 and 12.5 dpc (Figures 1I–L and 2A–H), Sox5
was absent from most Mitf-expressing cells at 16.5 dpc
and postnatal day 3 (Figure 2I–P). This argues that
Sox5 is expressed during embryonic development in mela-
noblasts, but disappears from these cells with their diﬀer-
entiation to melanocytes.
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oligodendroglial cells to be coexpressed with the closely
related Sox6 (9,44,45), we also assessed Sox6 expression.
Between 10.5 and 12.5 dpc, Sox6 amounts in melanoblasts
were as low as in many cells of the surrounding tissue, and
signiﬁcantly less than those in epidermal cells (Figure 1M
and data not shown). With this low expression levels, mel-
anoblasts are clearly not a prime site of Sox6 expression
(Figure 1M–P). Sox13, as the third SoxD protein was not
detected in melanoblasts (Figure 1Q–T). Therefore, we
considered it unlikely that Sox6 and Sox13 play major
roles in melanoblasts, and concentrated on Sox5.
Sox5deletion has nomajor impact on melanoblast
development by itself but modulates theconsequences
ofSox10 heterozygosity
Taking the widespread expression in melanoblasts into
account, we next asked whether loss of Sox5 would
inﬂuence the early stages of melanocytic development.
Whole-mount in situ hybridizations were performed on
Sox5
 /  embryos at 10.5 and 11.5dpc to follow melano-
blast development and results were compared with age-
matched wild-types (Figure 3 and data not shown). Care
was taken that analyzed embryos throughout our studies
were in a very similar stage of development and had a
comparable genetic background. Using c-Kit, Dct and
Mitf as three independent markers of the early melanocyte
lineage, we failed to detect any signiﬁcant diﬀerence in the
appearance or migration pattern of melanoblasts in
Sox5
 /  embryos (compare Figure 3A, E, I and M to
Figure 3B, F, J and N). Melanoblast numbers were also
comparable between Sox5
 /  embryos and their wild-type
littermates (Figure 3Q and R). The fact that the absolute
number of melanoblasts was twice as high with Dct as
with Mitf as probe, simply reﬂects the diﬀerent sensitiv-
ities of the respective probes. Distribution and number of
melanocytes were also normal in Sox5
 /  mice at the time
of birth (data not shown). Our analyses thus revealed that
Sox5 is dispensable for speciﬁcation of melanoblasts and
the consecutive phases of melanocyte development.
This contrasts dramatically with the previously reported
impact of Sox10 on development of the melanocyte line-
age (19,22,46). Already loss of a single Sox10 allele led to a
severe impairment of early development of the melanocyte
lineage that only partially recovered at later times. In
accord with previous ﬁndings, all melanocyte markers
were dramatically reduced in Sox10
+/lacZ embryos at
Figure 1. Sox gene expression in melanoblasts. Expression of Sox5
(A, C, I and K), its long isoforms (E and G), Sox6 (M and O),
Sox13 (Q and S) and Sox9 (U and W) (all shown in red) was compared
to occurrence of Sox10 (B, C, F and G) and Mitf (J, K, N, O, R, S, V
and W) (both shown in green) by co-immunohistochemistry on trans-
verse sections from the forelimb region of wild-type embryos at
11.5dpc. To visualize the region in which double positive cells were
found, nuclei were counterstained with DAPI (D, H, L, P, T and X).
Figure 2. Sox5 gene expression in the melanocyte lineage. Expression
of Sox5 (A, C, E, G, I, K, M and O) (red) was compared to occurrence
of Mitf (B, C, F, G, J, K, N and O) (green) on transverse sections from
the forelimb region of wild-type mice at 10.5 dpc (A–D), 12.5 dpc
(E–H), 16.5 dpc (I–L) and postnatal day 3 (P3) (M–P). To visualize
the region in which double positive cells were found, nuclei were coun-
terstained with DAPI (D, H, L and P).
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expression was aﬀected even stronger than that of the
other two markers (compare Figure 3Q to Figure 3R),
had been previously observed and was attributed to
direct dependence of Dct expression on high Sox10
levels in the mouse (19,22,31–33).
We used the Sox10
+/lacZ embryos to ask whether a role
of Sox5 in melanocyte development could be visualized on
this sensitized background. Therefore we generated
Sox5
 / , Sox10
+/lacZ double mutant embryos and
compared development of the melanocyte lineage in this
genotype with that in the two single mutants.
Figure 3. Melanoblast development in embryos with Sox5 deﬁciency and/or Sox10 heterozygosity. (A–P) Whole-mount in situ hybridizations were
performed on wild-type (A, E, I and M), Sox5
 /  (B, F, J and N), Sox10
+/lacZ (C, G, K and O) and Sox5
 / , Sox10
+/lacZ (D, H, L and P) embryos
at 10.5 dpc using antisense riboprobes against c-Kit (A–H), Dct (I–L) and Mitf (M–P). Results for c-Kit are shown both in low (A–D) and high
(E–H) magniﬁcation with the magniﬁed region boxed in the overviews. For Dct and Mitf, only high magniﬁcations from the forelimb area are
shown. (Q and R) Total Dct-( Q) and Mitf-positive cells (R) were quantiﬁed in age-matched wild-type, Sox5
 /  and Sox10
+/lacZ embryos as well as
their Sox5
 / , Sox10
+/lacZ littermates. Six embryos were counted for each genotype. The number of cells counted per embryo is presented as mean 
standard deviation. Cell numbers for the Sox5
 /  genotype were comparable to the wild-type, whereas dramatic reductions were observed for the
Sox10
+/lacZ embryos. The diﬀerence in cell counts between the Sox5
 / , Sox10
+/lacZ embryos and the Sox10
+/lacZ embryos were statistically
signiﬁcant as determined by Student’s t-test (
  P<0.01).
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the melanocytic phenotype of the Sox10
+/lacZ embryos,
although melanoblast numbers remained signiﬁcantly
below those in the wild-type and Sox5-deﬁcient embryos
(Figure 3D, H, L and P). Quantiﬁcation revealed that the
number of Dct-positive cells recovered from 2% to 8%
of wild-type levels (Figure 3Q). For Mitf, recovery was
from 30% to 70% of wild-type levels (Figure 3R). A simi-
lar increase of melanoblast numbers in the Sox5
 / ,
Sox10
+/lacZ double mutant relative to Sox10
+/lacZ
embryos was also detected at 11.5dpc (data not shown).
The most parsimonious explanation for this ﬁnding is that
Sox5 normally counteracts the activity of Sox10 during
early development of the melanocyte lineage so that its
loss leads to a partial phenotypic rescue in Sox10
+/lacZ
embryos. Rates of proliferation and apoptosis were
furthermore comparable for Mitf-expressing cells in all
genotypes (data not shown) arguing that Sox5, like
Sox10, already has an inﬂuence on melanocyte
speciﬁcation.
As observed previously, melanoblasts were completely
absent in Sox10
lacZ/lacZ embryos (19). Additional loss
of Sox5 did not lead to a recovery of melanoblasts in
Sox5
 / , Sox10
lacZ/lacZ embryos conﬁrming that some
amount of Sox10 must be present for Sox5 to exert its
function (data not shown).
Sox5hasthe capacityto bindto Sox10 response
elements inmelanocytic targetgenes ofSox10
Sox10 has previously been shown to activate Mitf and
Dct as its target genes (25–29,32–34). Depending on the
studied organism, Mitf gene activation has been proposed
to be one of the essential functions or the sole essential
task of Sox10 during melanocyte development (23,31).
Multiple binding sites for Sox10 have been mapped
within the Mitf and Dct promoters. These sites have
been found to diﬀerentially contribute to overall promoter
activation. In the Dct promoter, the S1 and the S4/40 sites
have been reported to be mainly responsible for the
Sox10-dependent induction (32). The same holds true
for site 5 in case of the Mitf promoter (25). The S1 site
from the Dct promoter and the site 5 from the Mitf pro-
moter are furthermore representative of response elements
recognized by Sox10 monomers, whereas S4/40 allows
binding of Sox10 dimers as evident from the mobility of
the Sox10-containing complexes on these sites in EMSA
(Figure 4A) (25,32). We asked whether Sox5 has the capa-
city to recognize these response elements. When EMSA
were performed with the long isoform of Sox5 that we
had detected in melanoblasts at 10.5 dpc, binding was
detected to all three sites (Figure 4A). From the compar-
able mobility of the Sox5-containing complex on site 5
and S1 relative to the S4/40 site, it can furthermore be
concluded that the L-Sox5 isoform binds to all sites as a
dimer in agreement with its constitutive dimerization in
solution (3).
As both Sox5 and Sox10 bound to the same response
elements in the Mitf and Dct promoters, we analyzed
whether simultaneous binding to these sites can occur or
whether binding is mutually exclusive. For this purpose,
Sox5 and Sox10 were together incubated with each of the
three sites (Figure 4B–D). For better visualization, a car-
boxyterminally truncated Sox10 version was used. In
EMSA, only complexes were observed whose mobility
corresponded to the Sox5- or the Sox10-containing com-
plex. Additional supershift experiments with Sox5- and
Sox10-speciﬁc antibodies conﬁrmed that the complexes
with Sox5- or Sox10-speciﬁc mobility indeed contained
only one of the two Sox proteins (Figure 4B–D). Similar
results were obtained when full-length Sox10 was
used instead of the truncated version (data not shown).
From the unchanged composition of the complexes
and our failure to obtain novel complexes with intermedi-
ate or higher mobility, a mutually exclusive mode of
binding is concluded. This was also conﬁrmed in titration
experiments in which increasing amounts of Sox10
were capable of displacing a ﬁxed amount of Sox5
from S4/40 (Figure 4E) just as increasing amounts of
Sox5 were capable of displacing a ﬁxed amount of
Sox10 without the appearance of any additional complex
(Figure 4F).
Sox5prevents Sox10 frominducing thepromoters of its
melanocytic targetgenes
We next addressed the ability of both Sox proteins to
inﬂuence the activities of the Mitf and Dct promoters in
luciferase reporter assays. Whereas Sox10 robustly acti-
vated both promoters in transiently transfected Neuro2a
cells, no such activation was observed for the long Sox5
isoform (L-Sox5) over a broad range of concentrations
(Figure 5A and B and data not shown). This agrees with
previous ﬁndings that all Sox5 isoforms lack a classical
transactivation domain (3). When reporter genes were
cotransfected simultaneously with both Sox proteins,
Sox10 furthermore lost its ability to eﬃciently activate
either the Dct promoter (Figure 5A) or the Mitf promoter
(Figure 5B). We thus conclude that the long Sox5 isoform
counteracts the transcriptional activity of Sox10 on its
melanocytic target gene promoters in heterologous cell
lines. Qualitatively similar results were also obtained in
transiently transfected B16 melanoma cells (Figure 5C
and D), although Sox10-dependent activation rates were
lower, likely because of the presence of endogenous Sox10
in these cells (47) (see also Figure10A and B).
Because Neuro2a cells have a neural crest origin and at
the same time provide a Sox10-free background, we con-
tinued our luciferase reporter assays in these cells. When
constant amounts of Sox10 were challenged with increas-
ing amounts of Sox5, Sox10-dependent activation of both
Dct and Mitf promoters was counteracted by the long
Sox5 isoform in a concentration-dependent manner
(Figure 5E and F). Similar to the long isoform, the short
Sox5 isoform did not activate Dct promoter or Mitf
promoter on its own (Figure 5G and H). Interestingly,
however, the short Sox5 isoform failed to inhibit Sox10-
dependent activation. We thus conclude that the ability
to modulate Sox10 activity on these promoters is res-
tricted to the long isoform of Sox5 which is present in
melanoblasts.
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Using the B16 cell line, we next investigated whether Sox5
is also expressed in melanoma cells. First, we searched for
the presence of Sox5 transcripts. RT–PCR studies
revealed that B16 cells not only contained Sox10, Dct
and Mitf transcripts, but also signiﬁcant levels of Sox5
transcripts (Figure 6A). Sox6 and Sox9 transcripts were
also detected (Figure 6A) in agreement with previous
studies (48,49). Sox6 expression is thus clearly higher in
B16 melanoma than in melanoblasts at 11.5 dpc. The same
discrepant expression was also observed for Sox9 which is
strongly expressed in B16 melanoma, but virtually absent
from melanoblasts in mouse embryos (Figure 1U–X),
again in good agreement with previously published
data (49). The presence of Sox6 and Sox9 in B16 mela-
noma constitutes a signiﬁcant complication as functional
Figure 4. Sox5 recognizes binding sites for Sox10 in the Dct and Mitf promoters. (A) Binding of the long Sox5 isoform to bona ﬁde Sox10
recognition elements was studied in EMSA with the monomeric Sox10 binding site S1 and the dimeric site S4/40 from the Dct promoter and the
binding site 5 from the Mitf promoter as probes (25,32). Extracts from transfected Neuro2a cells served as source for full-length Sox10 and Sox5.
Unspeciﬁc complexes (ns) were identiﬁed as those that also appeared with extract from mock-transfected Neuro2a cells (C). Each of the speciﬁc
complexes is labeled on the right side of the panel for the presence of Sox5, Sox10 dimers (Sox10 D) or Sox10 monomers (Sox10M) in the respective
complexes. The ‘ ’ depicts no extract added. Using the S1 (B), S4/40 (C) and Mitf (D) probes, EMSA was performed with extracts from transfected
Neuro2a cells containing the carboxyterminally truncated MIC variant of Sox10 and/or Sox5. Addition of antibodies directed against Sox10 (a-
Sox10) or Sox5 (a-Sox5) during the incubation period was used to identify the complexes containing either Sox protein. Supershifted complexes are
marked by asterisks on the right side of the panels. No heteromeric complexes were observed. For titration experiments, a ﬁxed amount of Sox5 and
S/S40 were challenged with increasing amounts of Sox10 (E), or a ﬁxed amount of Sox10 and S/S40 were reciprocally incubated with increasing
amounts of Sox5 (F). As higher amounts of extract have to be used to obtain a Sox5-speciﬁc complex than a Sox10-speciﬁc complex, unspeciﬁc
complexes become apparent with increasing Sox5 amounts.
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possible in this cell line. In contrast, such a functional
compensation is unlikely in vivo, as melanoblasts only
express Sox5 and Sox10 in signiﬁcant amounts. Sox13
was similarly absent from 11.5 dpc melanoblasts and
B16 melanoma cells (Figure 1Q–T and Figure 6A).
Sox5 was also detectable on the protein level in
B16 melanoma cells by western blotting (Figure 6B).
As judged by its molecular weight, most of the Sox5
protein corresponded to the L-Sox5 isoform (Figure 6B).
This Sox5 protein was also responsible for one of
the complexes obtained in EMSA with the Mitf site 5
and B16 extract as judged by antibody supershift
experiments (Figure 6C). The Sox5-speciﬁc complex was
signiﬁcantly less intense than the Sox10-containing com-
plex, which furthermore exhibited a higher mobility as
predicted from the previous results with ectopically
expressed Sox proteins (see Figure 4A). This lower
amount of the Sox5-speciﬁc complex could either be due
to a lower aﬃnity of Sox5 for the Mitf site in the context
of the B16 extract or to lower amounts of the protein.
Taking the results from western blotting into account
(Figure 6B), lower amounts appear to be at least a con-
tributing factor.
To study the occurrence of Sox proteins in B16 cells on
a cellular level, we also performed co-immunocytochemis-
try. The vast majority of analyzed B16 cells indeed
expressed Sox5 (compare Figure 7A and E to Figure 7D
and H) as well as Sox6 (compare Figure 7I to Figure 7L)
and Sox9 (compare Figure 7Q to Figure 7T), but not
Sox13 (compare Figure 7M to Figure 7O and P).
Importantly, B16 cells were also quite homogenous
regarding their expression of Sox10 (Figure 7B) and
Mitf (Figure 7F, J, N and R). As a consequence, Sox5,
Sox6 and Sox9 were all coexpressed in most B16 cells with
Sox10 as well as Mitf (Figure 7C, G, K and S).
Sox5 represses Sox10-dependent targetgene expression
in B16 melanoma cells
Despite this complex Sox protein expression pattern, the
impact of Sox5 on the expression of Sox10 target genes
was assessed in B16 melanoma cells by transfection with
shRNA vectors. Using GFP expressed from the IRES-
EGFP cassette of the shRNA plasmid, we identiﬁed the
transfected cells and analyzed the amount of Sox proteins
in these cells relative to untransfected neighboring cells.
These studies revealed that a Sox10-speciﬁc shRNA
reduced the amount of Sox10, but not of Sox5 in B16
melanoma cells (Figure 8A, B, E and F), whereas a
Sox5-speciﬁc shRNA reduced the Sox5, but not the
Sox10 amounts (Figure 8M, N, Q and R). The Sox5-
speciﬁc shRNA likewise had no inﬂuence on the Sox6
amounts in transfected cells (Figure 9A and B).
Furthermore, scrambled versions of the Sox5-speciﬁc or
the Sox10-speciﬁc shRNAs did not change the level of
either Sox protein and served as controls (Figure 8C, D,
G, H, O, P, S and T). Concomitant with a reduction of
endogenous Sox10 levels, there was also a dramatic reduc-
tion of Mitf amounts in >90% of all B16 cells transfected
with a Sox10-speciﬁc shRNA (Figure 8I and J), thus
Figure 5. Sox5 counteracts the Sox10-dependent activation of melanocyte-speciﬁc promoters. Transient transfections were performed in Neuro2a
(A, B, E, F, G and H) and B16 (C and D) cells using reporter plasmids in which the luciferase gene was under control of 1.1kb of the Dct (A, C, E
and G) or 1.5kb of the Mitf (B, D, F and H) promoter. Expression plasmids for Sox10, the long (L-Sox5) and the short (S-Sox5) isoform of Sox5
were cotransfected as indicated below the bars in amounts of 100ng each, with exception of Sox5 in panels (E) and (F) where plasmid amounts for
L-Sox5 varied between 10, 20, 50, 100 and 200ng. Transactivation rates for each promoter are presented as fold inductions SEM. Luciferase
activities were determined in three experiments each performed in duplicates. The inlay in panel (H) shows both L-Sox5 and S-Sox5 detected on a
western blot with an anti-Sox5 antiserum.
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In contrast, >90% of B16 cells transfected with a Sox5-
speciﬁc shRNA or the scrambled shRNA versions
exhibited unaltered Mitf levels (Figure 8K, L, U, V, W
and X). These experiments conﬁrm on a cellular level that
on its own endogenous Sox10, but not Sox5 inﬂuences
Mitf expression in melanocyte-derived cells.
When B16 melanoma cells were simultaneously trans-
fected with equal amounts of Sox5- and Sox10-speciﬁc
shRNA vectors, we detected substantial amounts of Mitf
in approximately two-thirds of the transfected cells
(Figure 8Y and Z). We take this as evidence that a con-
comitant reduction of endogenous Sox5 levels relieves the
impact of decreased Sox10 amounts on Mitf expression.
The fact that Mitf levels diﬀer substantially among
transfected cells is probably caused by cell-to-cell varia-
tions in the residual amounts of Sox5 and Sox10. If, for
instance, Sox10 levels are lowered by shRNA below
threshold levels, concomitant Sox5 reductions probably
remain without eﬀect. Nevertheless, our results are com-
patible with a model in which Sox5 antagonizes Sox10
target gene activation in cells of melanocytic origin.
Analogous experiments were also carried out with a
Sox6-speciﬁc shRNA vector. As expected, Sox6 levels
were speciﬁcally reduced by the shRNA (Figure 9C and
D), whereas Sox5, Sox10 and Mitf levels remained unaf-
fected (Figure 9E–J). Reduction of Sox6 levels, however,
failed to counteract the eﬀects of Sox10-speciﬁc shRNA
on Mitf expression (Figure 9K and L). This may indicate
that Sox5 and Sox6 are not functionally redundant in their
Sox10-modulating activity in these cells. Alternatively,
both proteins are functionally redundant, but occur at
substantially diﬀerent amounts, with Sox6 amounts
being signiﬁcantly lower than Sox5 amounts in B16
melanoma.
Figure 6. Sox5 is coexpressed with other Sox genes in B16 melanoma
cells. (A) PCR experiments were performed on DNaseI-treated, reverse
transcribed RNAs from B16 melanoma cells (B16) and spinal cords of
7-day old mice (P7), the latter serving as a positive control as most Sox
genes are known to be expressed in this tissue. Transcripts were
detected with mouse-speciﬁc primers for Sox5, Sox6, Sox13, Sox9,
Sox10, Dct, Mitf and  -actin. Template-free control reactions were
performed in parallel ( ). (B) Equal amounts of extracts from B16
melanoma cells were subjected to SDS–PAGE and western blotting
using antibodies directed against Sox5, Sox10 and acetylated a-tubulin.
On the right side, the size of coelectrophoresed molecular weight mar-
kers are given. (C) EMSA was performed with the binding site from the
Mitf promoter as probe and extracts from B16 melanoma cells.
Addition of antibodies directed against Sox10 (a-Sox10) or Sox5
(a-Sox5) to the reactions during the incubation period was used to
identify the Sox5- and Sox10-containing complexes, respectively. The
‘ ’ depicts no extract added.
Figure 7. Sox5 is coexpressed on a cellular level with other Sox proteins
and Mitf in B16 melanoma cells. Immunocytochemistry was carried out
on B16 melanoma cells using antibodies against the long Sox5 isoform
(A, C, F and G), Sox6 (I and K), Sox13 (M and O) and Sox9 (Q and S)
(in red). B16 melanoma cells were additionally counterstained with
antibodies directed against Sox10 (B and C) and Mitf (E, G, J, K,
N, O, R and S) (all in green). Panels (A, B, E, F, I, J, M, N, Q and
R) show single color recordings, panels (C, G, K, O, S) merged pic-
tures. Nuclei of B16 melanoma cells were counterstained with DAPI
(D, H, L, P and T).
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role of Sox5, we cotransfected luciferase reporters under
the control of the Dct or Mitf promoter in B16 melanoma
cells with the Sox5- and Sox10-speciﬁc shRNA vectors.
When luciferase activities were determined 2 days
posttransfection, we observed a signiﬁcantly reduced
expression of both reporters in the presence of the
Sox10-speciﬁc shRNA (Figure 10A and B). When
the expression plasmids for the Sox5-speciﬁc shRNA or
the scrambled control versions were cotransfected instead,
activities of both Dct and Mitf promoters remained unaf-
fected (Figure 10A and B and data not shown).
Intriguingly, simultaneous transfection of equal amounts
Figure 8. Sox5 and Sox10 inﬂuence melanocyte-speciﬁc gene expression
in B16 melanoma cells. Immunocytochemistry was carried out on B16
melanoma cells transfected with an shRNA vector speciﬁc for Sox10
(A, B, E, F, I and J), the corresponding scrambled version (C, D, G, H,
K and L), an shRNA vector for Sox5 (M, N, Q, R, U and V), its
corresponding scrambled version (O, P, S, T, W and X) and a combi-
nation of Sox5- and Sox10-speciﬁc shRNA vectors (Y and Z).
Immunocytochemistry was performed using antibodies against Sox10
(A–D, M–P), Sox5 (E–H, Q–T) and Mitf (I–L, U–Z); and immunola-
beling is shown in red. Transfected cells were visualized by GFP auto-
ﬂuorescence (B, D, F, H, J, L, N, P, R, T, V, X and Z) (green color).
Arrowheads indicate transfected cells in which expression of
endogenous proteins is lost or signiﬁcantly reduced.
Figure 9. The inﬂuence of Sox6 on melanocyte-speciﬁc gene expression
in B16 melanoma cells. Immunocytochemistry was carried out on B16
melanoma cells transfected with an shRNA vector speciﬁc for Sox5
(A and B), for Sox6 (C–J) and a combination of Sox6- and Sox10-
speciﬁc shRNA vectors (K and L). Immunocytochemistry was per-
formed using antibodies against Sox6 (A–D) Sox5 (E and F), Sox10
(G and H) and Mitf (I–L) (in red). Transfected cells were visualized by
GFP autoﬂuorescence (B, D, F, H, J and L) (green color). Arrowheads
indicate transfected cells in which expression of endogenous proteins is
lost or signiﬁcantly reduced.
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shRNA led to a statistically signiﬁcant partial recovery
of the activities of the Dct and the Mitf promoters when
compared to transfections in which only the Sox10-speciﬁc
shRNA was present. This argues that lowering of Sox5
amounts indeed helps to alleviate the eﬀects of Sox10
reductions on melanocyte-speciﬁc gene expression.
Sox5 is boundin B16 cells topromoters of melanocytic
Sox10 target genesand recruits transcriptional corepressors
We used chromatin immunoprecipitation assays to ask
whether Sox5 was also bound to Sox10 target gene
promoters in vivo. For this purpose, chromatin was pre-
pared from B16 melanoma cells and precipitated with con-
trol antibodies or antibodies directed against Sox5 and
Sox10 (Figure 10C). As expected, both Dct and Mitf pro-
moters were speciﬁcally enriched in the precipitate
obtained with the Sox10-speciﬁc antibody, but not in the
precipitate from control IgG reactions. Both promoters
were also preferentially immunoprecipitated from
chromatin when Sox5-speciﬁc antibodies were used. In
contrast to the promoter region, no enrichment was
observed in the immunoprecipitations for distal upstream
regions of the Dct and Mitf genes or the  -actin promoter
Figure 10. Sox5 binds to melanocyte-speciﬁc promoters and recruits transcriptional corepressors. (A and B) B16 melanoma cells were transiently
cotransfected with reporter plasmids in which the luciferase gene was under control of the Dct (A) or the Mitf (B) promoters, and expression
plasmids for shRNAs directed against Sox10 and Sox5 or their scrambled versions, as indicated below the bars. Promoter activity in the absence of
cotransfected shRNA was arbitrarily set to one and all other activities are expressed relative to this value SEM. Luciferase activities were
determined in three (A) and ﬁve (B) experiments each performed in duplicates. The higher transactivation rates obtained for both promoters in
the presence of both Sox5 shRNA and Sox10 shRNA as compared to Sox10 shRNA alone were statistically signiﬁcant as determined by Student’s
t-test (
  P<0.01). (C and D) Immunoprecipitation was performed on formaldehyde-ﬁxed chromatin from B16 melanoma cells in the absence ( ) and
presence of antibodies. In addition to control IgGs (IgG), antisera speciﬁcally directed against Sox5 (a-Sox5), Sox10 (a-Sox10), HDAC1 (a-HDAC1)
and CtBP2 (a-CtBP2) were employed. PCR was applied on the immunoprecipitate to detect the Dct promoter region (a) and the Mitf promoter
region (c) that contain the previously identiﬁed Sox10 response elements. Regions further upstream and more distal to the transcription start sites of
the Dct (b) and Mitf (d) genes were additionally ampliﬁed by PCR as controls. All fragments were recovered from 1/20 of the material used for
immunoprecipitation (input). (H2O), water control. (E) Neuro2a cells were transiently transfected using a reporter plasmid in which the luciferase
gene was under control of the 1.5kb Mitf promoter. Expression plasmids for Sox10, Sox5, HDAC1 and CtBP2 were cotransfected as indicated below
the bars. Whereas Sox10 expression plasmids were used at 100ng, Sox5 expression plasmids were employed at 20ng and HDAC1 or CtBP2
expression plasmids at 10ng per transfection reaction. Transactivation rates for each promoter are presented as fold inductions SEM.
Luciferase activities were determined in three experiments each performed in duplicates. (F) Immunoprecipitation with anti-HA tag antibodies
was performed on formaldehyde-ﬁxed chromatin from Neuro2a cells transiently transfected with expression plasmids for the long Sox5 isoform,
HA-tagged CtBP2 or their combination as indicated above the lanes. Mock-transfected Neuro2a cells ( ) served as control. PCR was applied on the
immunoprecipitate to detect the Mitf and the Dct promoter regions under the same conditions as in (C and D). (H2O), water control.
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precipitation thus conﬁrmed that Sox5 as well as
Sox10 occupy the Dct and Mitf promoters in B16 mela-
noma cells.
Previous studies on Fgf3 gene regulation in the inner ear
and cyclin D1 gene regulation in pancreatic b-cells had
shown that Sox6 inhibits gene expression by recruiting
the CtBP2 and HDAC1 corepressors to the respective
promoters (50,51). To address whether the eﬀects of the
closely related Sox5 on melanocytic gene expression
involved a similar mechanism, we ﬁrst checked by chro-
matin immunoprecipitation whether these corepressors
were also present on the Dct and Mitf promoters.
Indeed, we were able to precipitate higher amounts of
both promoters from B16 chromatin with anti-HDAC1
and anti-CtBP2 antisera than with control IgG, whereas
no enrichment was obtained in the HDAC1- or CtBP2-
speciﬁc precipitates for control fragments from the distal
upstream regions (Figure 10D).
Luciferase reporter assays in transiently transfected
Neuro2a cells furthermore showed that HDAC1 and
CtBP2 on their own had no signiﬁcant eﬀect on
Sox10-dependent activation of the Mitf promoter
(Figure 10E). Both were, however, capable of enhancing
the inhibitory eﬀects of limiting amounts of the long Sox5
isoform on Sox10-dependent promoter activation, sug-
gesting that recruitment of these corepressors to the Mitf
promoter can indeed occur via Sox5. Such a conclusion
was additionally strengthened by chromatin immunopre-
cipitation experiments on Neuro2a cells transiently trans-
fected with Sox5, a HA-tagged version of CtBP2 or a
combination of both, as enrichment of the Mitf promoter
in chromatin precipitated with an antibody against the
HA tag of CtBP2 was only observed when the long
Sox5 isoform was simultaneously present in the trans-
fected cell (Figure 10F).
DISCUSSION
Here, we have shown that Sox5 is expressed in the
melanocyte lineage during mouse embryonic development.
This extends previous ﬁndings on the occurrence of
Sox5 in early neural crest cells (15) and identiﬁes the mela-
nocyte lineage in addition to peripheral glia as the
second neural-crest-derived cell type in which Sox5 expres-
sion is maintained after the speciﬁcation event. In the
melanocyte lineage, Sox5 expression was restricted to
melanoblasts. Sox5 was furthermore the major SoxD
protein in melanoblasts where it occurred in its long
isoform.
Analysis of c-Kit, Dct and Mitf as three independent
markers revealed a surprisingly normal generation of
melanoblasts in Sox5-deﬁcient mice. Considering the
dominance of Sox5 expression over Sox6 or Sox13
expression in melanoblasts, it appears unlikely that a
melanocytic phenotype would be completely obscured in
Sox5-deﬁcient mice by other SoxD proteins, although
examples of coexpression and functional redundancy exist
for Sox5 and Sox6 in the development of other cell lin-
eages such as chondrocytes and oligodendrocytes (52,53).
As a consequence, single mouse mutants exhibited only
mild chondrocytic and oligodendrocytic phenotypes,
whereas the double mutant showed severe developmental
defects (7,9).
A fairly normal generation of melanoblasts would be
expected if Sox5 predominantly functioned as a modiﬁer
rather than a developmental regulator of its own. Sox5 has
indeed been previously reported to modulate the function
of the SoxE proteins Sox9 and Sox10. Sox5 enhances the
function of Sox9 during several consecutive phases of
chondrocyte development (44,54), but attenuates the
eﬀects of Sox9 on speciﬁcation and of Sox10 on terminal
diﬀerentiation during oligodendrocyte development (9).
Sox5 also performs such a modulatory role in early devel-
opment of the melanocyte lineage as indicated by the fact
that the dramatically reduced generation of melanoblasts
in Sox10 heterozygous embryos is partially restored by
additional deletion of Sox5. As already observed in the
oligodendrocyte lineage, Sox5 appears to counteract
the activity of Sox10.
In contrast to melanoblasts of the early mouse embryo,
B16 melanoma cells not only expressed Sox5 and Sox10,
but also Sox6 and Sox9. The melanoma is thus more com-
plicated than the melanoblast. Nevertheless, our results
from shRNA experiments in B16 melanoma cell cultures
were fully compatible with an antagonistic eﬀect of Sox5
on Sox10 activity.
Previous studies had failed to detect any direct protein–
protein interactions between Sox5 and Sox10 in solution
(9). There is thus no evidence that Sox5 may function by
sequestering Sox10 away from its target genes in inactive
complexes. Instead, Sox5 was detected by chromatin
immunoprecipitation on the same regulatory regions
that have previously been shown to mediate Sox10 respon-
siveness to its melanocytic target genes (25–29,32–34).
EMSA furthermore indicated that Sox5 binds to the
same sequences that are Sox10 response elements.
Because binding of Sox5 and Sox10 were mutually exclu-
sive in vitro, it can be assumed that competition for bind-
ing sites may be one of the ways in which Sox5 interferes
with the function of Sox10. However, it should be kept in
mind that most of the Sox10-responsive promoters and
enhancers contain multiple binding sites for this protein,
which contribute to diﬀerent extents to the overall rate
of induction (55). This is also the case for the melano-
cytic Sox10 target genes Dct and Mitf (25,28,29,32,34).
Competition for binding to a particular site therefore
does not exclude the possibility that both Sox5 and
Sox10 are bound to diﬀerent sites of the Dct or Mitf pro-
moter at the same time. Under these conditions, it is prob-
ably essential that Sox5 recruits the HDAC1 and CtBP2
transcriptional corepressors to the promoters of melano-
cytic Sox10 target genes as we have shown in this study.
A similar capability has previously reported for Sox6 in
its role as a repressor of Fgf3 gene expression in the
inner ear, cyclin D1 gene expression in pancreatic b-cells
and e-globin expression during deﬁnitive erythropoiesis
(12,50,51). Corepressor recruitment may thus be a
common feature of SoxD proteins.
Intriguingly, Sox5 has recently also been shown
to recruit coactivators to Sox9 target genes in chondrocytes
5438 Nucleic Acids Research, 2008, Vol. 36, No. 17and thereby enhance Sox9 function (56). With its ability
to alternatively recruit corepressors or coactivators in
diﬀerent developmental contexts, the ability of Sox5 to
modulate the activity of SoxE proteins is clearly
mechanistically complex and likely to have multiple
facets.
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